Pharmacoeconomic analysis of the self-monitoring blood glucose use in the diabetes mellitus patients treatment in the Russian Federation
In Russia, as in all countries of the world, there is a significant increase in the prevalence of diabetes: from 2000 to 2018. the number of diabetic patients increased by 2.5 million. However, these data underestimate the real number of patients, since only identified and registered cases of the disease are taken into account. The real number of patients with diabetes in the Russian Federation is at least 8-9 million people (about 6% of the population), which poses an extreme threat to the long-term perspective. The aim of this study was to determine, from the point of view of pharmacoeconomic analysis, the predominant self-monitoring blood glucose (glucometer with test strips) used in the complex treatment of diabetes mellitus based on a comparison of the ratio between costs and effectiveness, safety and quality of life when using Accu-Chek Performa (ACP) in comparison with the Russian satellite Express (SE) glucometer. According to the efficiency analysis, ACP model use is more effective than the SE model. As a result of the cost-effectiveness analysis, it was revealed that in comparison with the use of the SE model, ACP is the dominant medical technology. The budget impact analysis determined that the ACP scheme results in savings in the health system budget.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link: Kulikov A.Yu., Kostina E.O. Pharmacoeconomic analysis of the self-monitoring blood glucose use in the diabetes mellitus patients treatment in the Russian Federation // Pharmacoeconomics: theory and practice. - 2020. - Т.8, №2. - С. 17-21 DOI: https://doi.org/10.30809/phe.2.2020.2